---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-040919"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:42:39.739344+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vor Bio announces additional Phase 1/2a data: trem-cel protects against Mylotarg hematotoxicity in AML patients

## Summary
- First AML patient maintained neutrophil and platelet counts ~5 months post trem-cel transplant through three Mylotarg doses at 0.5 mg/m².
- No Mylotarg-related hematotoxicity observed; only low-grade nausea/vomiting reported as possibly related.
- Second patient engrafted normally with neutrophil recovery Day 11, platelet recovery Day 17; no unexpected AEs in both patients.
- CD33-negative donor hematopoiesis enriched across cell types after Mylotarg, suggesting potential for combo therapy.
- Company on track to file IND in H1 2023 for VCAR33 ALLO allogeneic CAR-T to combine with trem-cel.

## SEC filing metadata
- accession: 0001193125-23-040919
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312523040919/0001193125-23-040919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312523040919/d449789d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-040919
- JSON: https://secwatch.observer/filing/0001193125-23-040919.json
- Plain text: https://secwatch.observer/filing/0001193125-23-040919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.